HYBRID RETROVIRUS AND ITS REPLICATION

混合逆转录病毒及其复制

• 批准号: 2643930
• 负责人: VIT LAUERMANN
• 金额: $ 10万
• 依托单位: RUBICON LABORATORY, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-06-01 至 1999-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2643930
• 关键词: Retroviridae; cell line; gel electrophoresis; murine leukemia virus; nucleic acid sequence; protein engineering; recombinant virus; southern blotting; transfection; transfection /expression vector; virus genetics; virus replication

The aim of this project is to construct and characterize a new type of hybrid retrovirus that will use a novel replication strategy. This replication strategy will make the virus safer for use, either as a therapeutic or a preventive tool. It is the specific aim of this project to engineer this virus to allow for replication in human cells. The general objective of the project is to adapt this hybrid virus for use in gene therapy and for vaccines. Because of the obvious importance of safety issues to public health and medicine, these new retroviral entities will have broad application in biotechnology and medicine as safer, and perhaps more efficient, vectors for transfer of genes into animals and humans in need of gene therapy and as safer vaccines against viral disease and cancer. The hybrid viruses will be constructed and tested using standard molecular biology techniques, and they will consist entirely of available DNA plasmid sequences. These novel retroviruses will open a new field into research of retroviral replication that will result in a better understanding of this process and could potentially lead to a new and more efficient approaches in treatment of viral diseases. PROPOSED COMMERCIAL APPLICATION: The potential commercial applications of this research are: in health care and medicine, more specifically in gene therapy, anti-viral vaccines, and cancer vaccines.

该项目的目的是构建和表征一种新型的 将使用新型复制策略的混合逆转录病毒。 这 复制策略将使病毒更安全的使用，无论是作为一个 治疗或预防工具。 这是一个具体的目的， 该项目旨在改造这种病毒，使其能够在人类细胞中复制。 该项目的总体目标是使这种混合病毒适应 用于基因治疗和疫苗。 因为显而易见的重要性 考虑到公共卫生和医学的安全问题，这些新的逆转录病毒 实体将广泛应用于生物技术和医学， 更安全，也许更有效的载体，用于将基因转移到 需要基因治疗的动物和人类， 病毒性疾病和癌症。 将构建杂交病毒， 使用标准的分子生物学技术进行测试， 完全由可用的DNA质粒序列组成。 这些新颖 逆转录病毒将为逆转录病毒的研究开辟新的领域 这将有助于更好地理解这一过程 并可能导致一种新的更有效的方法， 治疗病毒性疾病。 拟定商业应用： 这项研究的潜在商业应用包括： 护理和药物，更具体地说，在基因治疗，抗病毒， 疫苗和癌症疫苗。